Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases.

De Simone C, Sollena P, Coco V, Caldarola G.

G Ital Dermatol Venereol. 2013 Apr;148(2):175-84. Review.

PMID:
23588143
2.

Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.

Passarini B, Infusino SD, Barbieri E, Varotti E, Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M.

Dermatology. 2007;215(4):295-300.

PMID:
17911986
3.

Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.

Buisson A, Cuny JF, Barbaud A, Schmutz JL, Bigard MA, Guéant JL, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2012 May;35(10):1175-80. doi: 10.1111/j.1365-2036.2012.05082.x. Epub 2012 Apr 2.

4.

Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.

Guerra I, Algaba A, Pérez-Calle JL, Chaparro M, Marín-Jiménez I, García-Castellanos R, González-Lama Y, López-Sanromán A, Manceñido N, Martínez-Montiel P, Quintanilla E, Taxonera C, Villafruela M, Romero-Maté A, López-Serrano P, Gisbert JP, Bermejo F.

J Crohns Colitis. 2012 Jun;6(5):518-23. doi: 10.1016/j.crohns.2011.10.007. Epub 2011 Nov 13.

PMID:
22398059
5.

Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders.

Hession MT, Gottlieb AB.

J Dermatolog Treat. 2011 Apr;22(2):90-101. doi: 10.3109/09546630903585090. Epub 2010 Aug 1. Review.

PMID:
20673155
6.

Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients.

Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, Aractingi S, Khosrotehrani K.

Medicine (Baltimore). 2008 Sep;87(5):281-93. doi: 10.1097/MD.0b013e318187cc9c.

7.

Dermatologic manifestations in inflammatory bowel disease in Tunisia.

Mebazaa A, Aounallah A, Naija N, Cheikh Rouhou R, Kallel L, El Euch D, Boubaker J, Mokni M, Filali A, Ben Osman A.

Tunis Med. 2012 Mar;90(3):252-7.

PMID:
22481199
8.

Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.

Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR.

Aliment Pharmacol Ther. 2011 Dec;34(11-12):1318-27. doi: 10.1111/j.1365-2036.2011.04866.x. Epub 2011 Sep 29. Review.

9.

Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.

Fiorino G, Allez M, Malesci A, Danese S.

Aliment Pharmacol Ther. 2009 May 1;29(9):921-7. doi: 10.1111/j.1365-2036.2009.03955.x. Epub 2009 Feb 10. Review.

10.

Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease.

Andrisani G, Guidi L, Papa A, Armuzzi A.

Eur Rev Med Pharmacol Sci. 2012 Jul;16(7):890-901. Review.

PMID:
22953637
11.

Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents.

Guerra I, Gisbert JP.

Expert Rev Gastroenterol Hepatol. 2013 Jan;7(1):41-8. doi: 10.1586/egh.12.64. Review.

PMID:
23265148
12.

The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.

Piérard GE, Piérard-Franchimont C, Szepetiuk G, Paquet P, Quatresooz P.

Expert Opin Biol Ther. 2010 Aug;10(8):1197-208. doi: 10.1517/14712598.2010.500283. Review.

PMID:
20560729
13.

Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.

Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE.

Am J Gastroenterol. 2011 Dec;106(12):2146-53. doi: 10.1038/ajg.2011.283. Epub 2011 Oct 25.

PMID:
22031357
14.

Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.

Perman MJ, Lovell DJ, Denson LA, Farrell MK, Lucky AW.

Pediatr Dermatol. 2012 Jul-Aug;29(4):454-9. doi: 10.1111/j.1525-1470.2011.01521.x. Epub 2011 Oct 13.

PMID:
21995665
15.

Long-term prognosis in patients with psoriasis.

Gulliver W.

Br J Dermatol. 2008 Aug;159 Suppl 2:2-9. doi: 10.1111/j.1365-2133.2008.08779.x. Review.

PMID:
18700909
16.

Treatment of the extraintestinal manifestations of inflammatory bowel disease.

Bernstein CN.

Curr Gastroenterol Rep. 2002 Dec;4(6):513-6. Review.

PMID:
12441042
17.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Collamer AN, Battafarano DF.

Semin Arthritis Rheum. 2010 Dec;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003. Epub 2010 Jun 26. Review.

PMID:
20580412
18.

Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.

Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P, Dernis E, Wendling D, Ansemant T, Berthelot JM, Bader-Meunier B, Kantelip B; Le CRI.

Joint Bone Spine. 2012 Oct;79(5):457-63. doi: 10.1016/j.jbspin.2011.10.001. Epub 2011 Nov 15.

PMID:
22088934
19.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.

PMID:
23032984
20.

Adalimumab for the treatment of inflammatory bowel disease.

Wasan SK, Kane SV.

Expert Rev Gastroenterol Hepatol. 2011 Dec;5(6):679-84. doi: 10.1586/egh.11.81.

PMID:
22017695

Supplemental Content

Support Center